Physician profile
Javier Arce
NPI 1962591743
$1,472.78
in general payments reported to CMS, 2019-2025
18 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.18 · 2021: $24.42 · 2022: $374 · 2023: $315 · 2024: $376 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $282.19 | 2019-2024 | Wainua |
| Merck Sharp & Dohme LLC | $261.07 | 2021-2023 | Verquvo |
| Medtronic, INC. | $213.34 | 2023-2025 | Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan, Micra |
| Amgen INC. | $147.02 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $131.02 | 2019-2024 | |
| Abbott Laboratories | $83.11 | 2023 | Aveir |
| Shockwave Medical, INC | $78.97 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $64.16 | 2024-2025 | Impella |
| Becton, Dickinson and Company | $38.69 | 2025 | Hemosphere |
| Bridgebio Pharma, INC. | $32.82 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $26.72 | 2024 | Arcalyst |
| Boston Scientific Corporation | $25.00 | 2023 | Avvigo Guidance System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.48 | 2023 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $18.81 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.10 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.90 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.51 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Arce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.